A second phase 1 trial plans to evaluate CER-1236, a novel chimeric antigen receptor therapy, for solid tumors.
2025
How midkine helps tumours evade immunotherapy
How midkine helps tumours evade immunotherapy
Mobile App Cuts Skin Cancer Referrals in Half, British Trial Shows
The Map My Mole app provides patients with a small lens attachment for their phones to capture high-quality images of concerning skin spots. These images are then uploaded for assessment by consultants.
Anti–LAG-3/Anti–PD-1 Combo Demonstrates Sustained Efficacy in Melanoma
Meredith McKean, MD, MPH, director of melanoma and skin cancer research at Sarah Cannon Research Institute, discusses the background and goals from the recent long-term follow-up of a phase 1 study (NCT03005782) evaluating the combination of fianlimab, an anti–LAG-3 agent, and cemiplimab (Libtayo), an anti–PD-1 agent, in patients with advanced melanoma.